Tuberculosis
Briefing Document - 13 Oct 2017
Drug-Resistant Tuberculosis Treatment & Access to Delamanid in South Africa
Delamanid is one of the first new medicines developed for DR-TB treatment in 50 years. The standard treatment duration is for the first six months of DR-TB treatment. The WHO issued interim guidelines on DLM use to treat MDR-TB in November 2014 and on its use in treating children and adolescents in 2016. Delamanid is also included in the 19th WHO Model List of Essential medicines.Briefing Document - 13 Oct 2017
Tuberculosis
Videos and Photos - 12 Oct 2017
The end of a long TB treatment journey
When 18-year old Sinethemba Kuse from Khayelitsha in South Africa was declared cured of extensively drug-resistant tuberculosis, her friends, family, doctors and counsellors threw her ‘cure party’.Videos and Photos - 12 Oct 2017
Drug-resistant TB
Press Release - 12 Oct 2017
Limited access to new TB drug delamanid.
Limited access to new drug delamanid reduces promising treatment options available for those with drug-resistant tuberculosis.Press Release - 12 Oct 2017
Multi-drug Resistant Tuberculosis
Report - 11 Oct 2017
MDR-TB drugs cover less than 5% in need
Slow scale-up of newer MDR-TB drugs covers less than 5% in need.Report - 11 Oct 2017
Mental Health
Report - 11 Oct 2017
Confronting the mental health emergency on Samos and Lesvos.
Why the containment of asylum seekers on the Greek islands must end.Report - 11 Oct 2017
Multi-drug Resistant Tuberculosis
People still being denied improved treatment for MDR-TB
Latest News - 11 Oct 2017
Mental Health
Press Release - 11 Oct 2017
EU Border polices fuel mental health crisis for asylum seekers
MSF calls on authorities to immediately relocate asylum seekers to the Greek mainland.Press Release - 11 Oct 2017
Mental Health
“I am shocked by Europe"
I am shocked by Europe, a powerful statement reflecting concerns about humanitarian policies and MSF's advocacy. Fieldworkers Stories - 11 Oct 2017
Mental Health
